The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Irving, Texas-based McKesson Corporation (MCK) distributes pharmaceuticals, medical-surgical supplies, and health and beauty care products. With a market cap of $88.3 billion, the company also develops, implements, and supports software that facilitates the integration of data throughout the health enterprise. In addition, McKesson offers analytic, care management, and patient solutions for payers.

Companies worth $10 billion or more are generally described as “large-cap stocks.” MCK effortlessly fits that bill, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical distribution industry. MCK stands as one of the titans in the U.S. pharmaceutical distribution landscape with an expansive distribution network and comprehensive product offerings enabling it to meet diverse customer needs effectively. MCK's ability to offer a wide range of services, from drug distribution to medical-surgical supply and technology solutions, allows it to tap into various revenue streams and mitigate risks associated with any single line of business.

Investors Bearish on Oracle Ahead of Earnings - Unusually Heavy ORCL Put Options Trading

Salesforce vs. ServiceNow: 1 AI Giant Is Leaving the Other Behind

Microsoft Stock Is Up Nearly 30% From Its March Lows, But You Shouldn’t Sell MSFT Just Yet

Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!

Despite its notable strength, MCK slipped 26.2% from its 52-week high of $999, achieved on Mar. 3. Over the past three months, MCK stock has declined 25.7%, underperforming the Dow Jones Industrials Average’s ($DOWI) 4.9% gains during the same time frame.

Shares of MCK fell 10.2% on a YTD basis but climbed 2.1% over the past 52 weeks, underperforming DOWI’s YTD gains of 6.8% and 21.3% returns over the last year.

To confirm the bearish trend, MCK has been trading below its 200-day moving average since early May. The stock has been trading below its 50-day moving average since late March.

On May 7, MCK shares closed up by 1.5% after reporting its Q4 results. Its adjusted EPS of $11.69 topped Wall Street expectations of $11.56. The company’s revenue was $96.3 billion, falling short of Wall Street forecasts of $101.9 billion. MCK expects full-year adjusted EPS in the range of $43.80 to $44.60.

In the competitive arena of medical distribution, Cencora, Inc. (COR) has lagged behind MCK, with a 21.6% downtick on a YTD basis and 9.3% decline over the past 52 weeks.

Wall Street analysts are bullish on MCK’s prospects. The stock has a consensus “Strong Buy” rating from the 17 analysts covering it, and the mean price target of $966.73 suggests a potential upside of 31.2% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com